News & Updates

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Early resumption of antiplatelet therapy (APT) and anticoagulant therapy (ACT) ≤7 days after gastrointestinal bleeding (GIB) offers a favourable benefit–risk balance in patients with cardiovascular (CV) or cerebrovascular indications, according to a systematic review and meta-analysis conducted by researchers from the Chinese University of Hong Kong and Nanyang Technological University in Singapore.